NeuroSense Therapeutics (NRSN) Institutional Ownership $1.36 +0.08 (+6.25%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for NeuroSense Therapeutics (NASDAQ:NRSN)CurrentInstitutional OwnershipPercentage1.04%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$1.83MNumber ofInstitutional Sellers(last 12 months)0 Get NRSN Insider Trade Alerts Want to know when executives and insiders are buying or selling NeuroSense Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NRSN Institutional Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now NeuroSense Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2024 XTX Topco Ltd45,996$58K0.0%+40.9%0.336% 8/15/2024 Armistice Capital LLC1,584,000$1.77M0.0%N/A11.591% 8/12/2024 XTX Topco Ltd32,650$37K0.0%N/A0.239% 11/15/2023 Armistice Capital LLC662,000$470K0.0%-47.7%6.051% 5/11/2023 Meitav Investment House Ltd.95,000$193K0.0%N/A0.868% (Data available from 1/1/2016 forward) NRSN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NRSN shares? During the previous two years, the following institutional investors and hedge funds held shares of NeuroSense Therapeutics shares: Armistice Capital LLC ($1.77M), and Meitav Investment House Ltd. ($193K), XTX Topco Ltd ($58K).Learn more on NRSN's institutional investors. What percentage of NeuroSense Therapeutics stock is owned by institutional investors? 1.04% of NeuroSense Therapeutics stock is owned by institutional investors. Learn more on NRSN's institutional investor holdings. Which institutional investors have been buying NeuroSense Therapeutics stock? The following institutional investors have purchased NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($1.58M), Meitav Investment House Ltd. ($95K), and XTX Topco Ltd ($46.00K). How much institutional buying is happening at NeuroSense Therapeutics? Institutional investors have bought a total of 1,724,996 shares in the last 24 months. This purchase volume represents approximately $1.99M in transactions. Which NeuroSense Therapeutics major shareholders have been selling company stock? The following institutional investors have sold NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($604K). How much institutional selling is happening at NeuroSense Therapeutics? Institutional investors have sold a total of 604,000 shares in the last 24 months. This volume of shares sold represents approximately $428.84K in transactions. Related Companies RLYB Institutional Ownership GANX Institutional Ownership SCYX Institutional Ownership QTTB Institutional Ownership XLO Institutional Ownership CLNN Institutional Ownership ATNM Institutional Ownership LEXX Institutional Ownership CALC Institutional Ownership MRKR Institutional Ownership This page (NASDAQ:NRSN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
